These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 15731197

  • 1. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [Abstract] [Full Text] [Related]

  • 2. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
    Van de Velde S, Nguyen HA, Van Bambeke F, Tulkens PM, Grellet J, Dubois V, Quentin C, Saux MC.
    J Antimicrob Chemother; 2008 Sep; 62(3):518-21. PubMed ID: 18544595
    [Abstract] [Full Text] [Related]

  • 3. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
    Vallet CM, Marquez B, Ngabirano E, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
    [Abstract] [Full Text] [Related]

  • 4. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
    Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM.
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2429-37. PubMed ID: 15917543
    [Abstract] [Full Text] [Related]

  • 5. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.
    Lemaire S, Van Bambeke F, Tulkens PM.
    Int J Antimicrob Agents; 2011 Jul; 38(1):52-9. PubMed ID: 21596526
    [Abstract] [Full Text] [Related]

  • 6. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus.
    Seral C, Carryn S, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2003 May; 51(5):1167-73. PubMed ID: 12697643
    [Abstract] [Full Text] [Related]

  • 7. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
    Nguyen HA, Grellet J, Dubois V, Saux MC, Quentin C.
    J Antimicrob Chemother; 2007 Apr; 59(4):755-8. PubMed ID: 17353222
    [Abstract] [Full Text] [Related]

  • 8. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S, Ianniello F, Leone S, Esposito S.
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [Abstract] [Full Text] [Related]

  • 9. Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
    Shi G, Chen X, Wang H, Wang S, Guo X, Zhang X.
    J Antibiot (Tokyo); 2012 May; 65(5):229-36. PubMed ID: 22334239
    [Abstract] [Full Text] [Related]

  • 10. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model.
    Nguyen HA, Grellet J, Paillard D, Dubois V, Quentin C, Saux MC.
    J Antimicrob Chemother; 2006 May; 57(5):883-90. PubMed ID: 16533826
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

  • 12. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A, Schubert S.
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [Abstract] [Full Text] [Related]

  • 13. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
    Ulrich M, Berger J, Möller JG, Döring G.
    Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
    [Abstract] [Full Text] [Related]

  • 14. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, Llagostera M, Vila J.
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [Abstract] [Full Text] [Related]

  • 15. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
    Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM.
    J Antimicrob Chemother; 2005 Jun; 55(6):897-904. PubMed ID: 15860552
    [Abstract] [Full Text] [Related]

  • 16. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin.
    Imbuluzqueta E, Lemaire S, Gamazo C, Elizondo E, Ventosa N, Veciana J, Van Bambeke F, Blanco-Prieto MJ.
    J Antimicrob Chemother; 2012 Sep; 67(9):2158-64. PubMed ID: 22615297
    [Abstract] [Full Text] [Related]

  • 17. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA, Wagner RS, Jamison T, Bell B, Dajcs JJ, Stroman DW.
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [Abstract] [Full Text] [Related]

  • 18. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [Abstract] [Full Text] [Related]

  • 19. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.
    Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM.
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2095-103. PubMed ID: 12069960
    [Abstract] [Full Text] [Related]

  • 20. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.
    Lismond A, Tulkens PM, Mingeot-Leclercq MP, Courvalin P, Van Bambeke F.
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3040-6. PubMed ID: 18573933
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.